Tolerance to amphotericin B in clinical isolates of Candida tropicalis

Diagnostic Microbiology and Infectious Disease

Volumn 50, Issue 3, 2004, Pages 179-185

  Barchiesi, Francesco ^a   Maracci, Monia ^a   Baldassarri, Isabella ^a   Spreghini, Elisabetta ^a   Giannini, Daniele ^a   Scalise, Giorgio ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Amphotericin B; Candida tropicalis; Tolerance

Indexed keywords

AMPHOTERICIN B; POLYENE;

ANIMAL EXPERIMENT; ARTICLE; CANDIDA TROPICALIS; CANDIDIASIS; CONTROLLED STUDY; DILUTION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; FUNGUS ISOLATION; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA TROPICALIS; CANDIDIASIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; IMMUNOSUPPRESSION; MALE; MICE; MICE, INBRED STRAINS; MICROBIAL SENSITIVITY TESTS;

EID: 8444248626     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2004.06.002     Document Type: Article

References (20)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis. 24:1997;1122-1128
2. Beck-Sagué C.M., Jarvis W.R. National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis. 167:1993;1247-1251
3. Ernst E.J., Yodoi K., Roling E.E., Klepser M.E. Rates and extents of antifungal activities of amphotericin B, flucytosine, fluconazole, and voriconazole against Candida lusitaniae determined by microdilution, Etest, and time-kill methods. Antimicrob Agents Chemother. 46:2002;578-581
4. Geraghty P., Kavanagh K. Erythromycin, an inhibitor of mitoribosomal protein biosynthesis, alters the amphotericin B susceptibility of Candida albicans. J Pharm Pharmacol. 55:2003;179-184
5. Geraghty P., Kavanagh K. Disruption of mitochondrial function in Candida albicans leads to reduced cellular ergosterol levels and elevated growth in the presence of amphotericin B. Arch Microbiol. 179:2003;295-300
6. Ghannoum M.A., Rice L.B. Antifungal agents Mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 12:1999;501-517
7. Handwerger S., Tomasz A. Antibiotic tolerance among clinical isolates of bacteria. Rev Infect Dis. 7:1985;368-386
8. Klepser M.E., Wolfe E.J., Jones R.N., Nightingale C.H., Pfaller M.A. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob Agents Chemother. 41:1997;1392-1395
9. National Committee for Clinical Laboratory Standards (1997). Reference for broth dilution antifungal susceptibility testing of yeasts: Approved Standards M27-A. NCCLS, Wayne, PA
10. Nguyen M.H., Clancy C.J., Yu V.L., Yu Y.C., Morris A.J., Snydman D.R., Sutton D.A., Rinaldi M.G. Do in vitro susceptibility data predict the microbiologic response to amphotericin B? Results of a prospective study of patients with Candida fungemia. J Infect Dis. 177:1998;425-430
11. O'Keeffe J., Doyle S., Kavanagh K. Exposure of the yeast Candida albicans to the anti-neoplastic agent adriamycin increases the tolerance to amphotericin B. J Pharm Pharmacol. 55:2003;1629-1633
12. Pfaller M.A., Diekema D.J., Jones R.N., Sader H.S., Fluit A.C., Hollis R.J., Messer S.A. SENTRY Participant Group. International surveillance of bloodstream infections due to Candida species Frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J Clin Microbiol. 39:2001;3254-3259
13. Rex J.H., Cooper C.R., Merz W.J. Jr, Galgiani J.N., Anaissie E.J. Detection of amphotericin B-resistant Candida isolates in a broth-based system. Antimicrob Agents Chemother. 39:1995;906-909
14. Rex J.H., Pfaller M.A., Walsh T.J., Chaturvedi V., Espinel-Ingrof A., Ghannoum M.A., Gosey L.L., Odds F.C., Rinaldi M.G., Sheehan D.J., Warnock D.W. Antifungal susceptibility testing Practical aspects and current challenges. Clin Microbiol Rev. 14:2001;643-658
15. Sanglard D., Ischer F., Bille J. Role of ATP-binding-cassette transporters genes in high-frequency acquisition of resistance to azole antifungals in Candida glabrata. Antimicrob Agents Chemother. 45:2001;1174-1183
16. Tomasz A., Albino A., Zanati E. Multiple antibiotic resistance in a bacterium with suppressed autolytic system. Nature. 27:1970;138-140
17. Voorn G.P., Kuyvenhoven J., Goessens W.H., Schmal-Bauer W.C., Broeders P.H., Thompson J., Michel M.F. Role of tolerance in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis with vancomycin, teicoplanin, and daptomycin. Antimicrob Agents Chemother. 38:1994;487-493
18. White T.C., Marr K.A., Bowden R.A. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev. 11:1998;382-402
19. Wingard J.R., Merz W.J., Saral R. Candida tropicalis A major pathogen in immunocompromised patients. Ann Intern Med. 91:1979;539-543
20. Xu J., Onyewu C., Yoell H.J., Ali R.Y., Vilgalys R.J., Mitchell T.J. Dynamic and heterogeneous mutations to fluconazole resistance in Cryptococcus neoformans. Antimicrob Agents Chemother. 45:2001;420-427